Rashieda Gluck has been appointed vice president of Clinical Operations at Qu Biologics, Inc. Ms. Gluck will lead development, execution, and delivery of the company’s clinical trial programs. Qu Biologics develops Site Specific Immunomodulators (SSIs) that aim to 'reboot' the body's immune system to treat cancer and autoimmune disease.
Qu Biologics’ chief executive officer, Dr. Hal Gunn, said, "We are at an important stage of our growth with one clinical trial in Crohn's disease ongoing and other trials in cancer being planned. Rashieda's more than 20 years of clinical operations experience will be valuable to the development of our clinical programs as we further investigate the potential treatment benefits of our site specific immunomodulators. We are very pleased to welcome her to the leadership team."